Sun Pharma declines over 4% on unexpected Q2 loss

NEW DELHI: Shares of Sun Pharma dipped over 4 per cent in early trade on Wednesday after the pharma major posted a consolidated loss of Rs 218.82 crore for the quarter ended September 30, on a one-time loss of Rs 1,214.38 crore with respect to Modafinil antitrust litigation.

The scrip was trading 4.31 per cent down at Rs 537.50 at around 10.00 am (IST), while the benchmark BSE Sensex was down 0.19 per cent at 35,078.18.

The consolidated total revenue for the company increased 4.32 per cent year-on-year to Rs 6,937.63 crore during the quarter under review against Rs 6,650.34 crore in the same period last year.

Ebitda rose to Rs 1,530.90 crore during the September quarter against Rs 376 crore last year.


Meanwhile, the shares of Sun Pharma opened at Rs 558.50 on BSE against its previous close of Rs 561.70.